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Abstract
Background: The valid and reliable measurement of health service utilization, productivity losses
and consequently total disease-related costs is a prerequisite for health services research and for
health economic analysis. Although administrative data sources are usually considered to be the
most accurate, their use is limited as some components of utilization are not systematically
captured and, especially in decentralized health care systems, no single source exists for
comprehensive utilization and cost data. The aim of this study was to develop and test a
questionnaire for the measurement of disease-related costs for patients after an acute cardiac
event (ACE).
Methods: To design the questionnaire, the literature was searched for contributions to the
assessment of utilization of health care resources by patient-administered questionnaires. Based on
these findings, we developed a retrospective questionnaire appropriate for the measurement of
disease-related costs over a period of 3 months in ACE patients. Items were generated by
reviewing existing guidelines and by interviewing medical specialists and patients. In this study, the
questionnaire was tested on 106 patients, aging 35–65 who were admitted for rehabilitation after
ACE. It was compared with prospectively measured data; selected items were compared with
administrative data from sickness funds.
Results: The questionnaire was accepted well (response rate = 88%), and respondents completed
the questionnaire in an average time of 27 minutes. Concordance between retrospective and
prospective data showed an intraclass correlation (ICC) ranging between 0.57 (cost of medical
intake) and 0.9 (hospital days) with the other main items (physician visits, days off work,
medication) clustering around 0.7. Comparison between self-reported and administrative data for
days off work and hospitalized days were possible for n = 48. Respective ICCs ranged between 0.92
and 0.94, although differences in mean levels were observed.
Conclusion:  The questionnaire was accepted favorably and correlated well with alternative
measurement approaches. This first assessment showed promising characteristics of this
questionnaire in different aspects of validity for patients with ACE. However, additional research
and more extensive tests in other patient groups would be worthwhile.
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Background
The valid and reliable measurement of health service uti-
lization, productivity losses and consequently total dis-
ease-related costs is a prerequisite for health economic
analysis. While health effects can be measured by numer-
ous generic and disease-specific instruments [1-3], much
less work has been done regarding standardized methods
to measure health care utilization and disease-specific
costs.
Particularly when an economic evaluation is performed
prospectively alongside a clinical trial, cost data may be
collected by various methods, such as clinical records,
insurance data, and data from health care providers.
Patients may also provide data directly, by face to face
interviews, retrospective cost questionnaires, and prospec-
tive cost diaries. Overall, health economic studies com-
monly use cost data from administrative data sources and
routine databases from hospitals, health insurances, or
health care providers. They are usually considered to be
the most accurate method of cost measurement [4,5].
However, the use of administrative data has some signifi-
cant disadvantages. First, in economic evaluations adopt-
ing a societal perspective which includes all medical and
non-medical costs and potential savings related to the dis-
ease studied is broadly recommended [6,7]. Administra-
tive data, however, will typically miss some cost
components that should be considered. These include
expenditures for over the counter drugs, travel expenses,
or costs resulting from paid or unpaid informal care.
These cost items are also essential if one is interested in
the economic impact on patients by different types of
treatment. Second, in decentralized health care systems,
including many social security systems and market-ori-
ented health systems, no single source exists for compre-
hensive cost data. When study patients are insured by
multiple payers or receive their medical care at multiple
sites, investigators must contact numerous third party
payers and service providers in order to collect compre-
hensive cost data. In this case, the use of administrative
data may not be feasible and may be inefficient even for a
small number of patients. Thus in practice, investigators
may rely to some degree on patient-reported data. How-
ever, this may lead to other problems typical of survey
studies, such as non-response and missing data. Face to
face interviews limit these problems but may be too costly
for large numbers of patients [8]. Diaries are considered to
be feasible and valid, and are advantageous in that they do
not rely on instantaneous recall [9]. They allow informa-
tion to be collected prospectively, which reduces the like-
lihood of recall error. However, once the diary is sent, it is
impossible to determine whether the information was
filled in promptly or after receiving reminder letters,
which might be weeks later. While cost diaries are well
accepted over the short term, significant problems have
been reported over longer time periods, with drop-out
rates of up to 50% of the study population over one year
[8,10,11]. Similar problems arise with diaries for clinical
trials and related health economic studies, where follow-
up periods of 6–12 months are typical. In this case, a ret-
rospective approach may be attractive. However, available
retrospective instruments are rarely validated [9,12]. To
our knowledge, there is no tested instrument available
that was designed to comprehensively measure the full
range of direct and indirect medical and non-medical
costs alongside a clinical trial in cardiac patients.
The aim of this study was to develop and test a patient-
administered instrument for a clinical trial, which would
allow comprehensive cost measurements related to car-
diac disease over a longer time period without exceeding
normal recall periods.
Thus, the objective of this article is (1) to introduce the
instrument and its development, (2) to assess its accept-
ance and feasibility, and aspects of its validity in a clinical
trial setting, (3) to identify the cost structure and the over-
all level of disease-related costs in patients after an acute
cardiac event.
Methods
Questionnaire development
The cost questionnaire was designed as a booklet with
instructions that allow the patients to complete it inde-
pendently; it was based on the format and wording of cost
diaries developed and introduced in studies of patients
with low back pain [13] and inflammatory bowel disease
[14].
An enclosed letter explained the study's aim and design
and a telephone number was provided in case of ques-
tions. Patients were instructed at the beginning of the
questionnaire to complete it alone. The cost items were
adapted to the specific utilization pattern of cardiac
patients after an acute event. These were based on pub-
lished treatment guidelines and interviews with cardiac
patients, cardiologists in private practice, and a physician
at the rehabilitation clinic.
"Filter questions" were used for each cost item to clarify
and to the improve user-friendliness of the questionnaire
items. These asked whether any of the subsequent disease-
related costs were incurred during the respective time
frame. Only if the subject answered "yes" were they
required to complete a subsequent table, in which fre-
quency and/or cost of utilization were to be specified. In
addition, the use of filter questions allowed "no" answers
to be distinguished from missing answers, which is an
important distinction when calculating mean costs.BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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A crucial issue in the development of the questionnaire
was to determine the appropriate time frame for the single
cost items based on literature regarding cognitive theory,
empirical results in survey research, and a recent review in
the field of health care [15]. The following factors were
identified and considered when determining the time
frame and the framing of questions in order to balance
underreporting due to recall error and potential overre-
porting due to so called "telescoping" effects. These are
errors in reporting incurred by the temporal displacement
of an event, which typically leads respondents to overre-
port utilization frequencies [16]:
￿ There is no single ideal time frame for the recall period
of a cost questionnaire. The appropriate recall time span
for different utilization variables differs with respect to the
nature of cost items [17-21].
￿ The less regularly an event occurs and the lower its sub-
jective impact is, the less likely it is to be recalled exactly
over the longer time frame [22].
￿ Respondents estimate, rather than count, relatively fre-
quent events. A longer time frame does not improve data
quality [11,23].
￿ Techniques of "bounded recall" should be used if possi-
ble [24]. This means, that the time horizon is explicitly
defined by exact dates and, for repeated measurements,
the preceding answers and already recalled events should
be shown.
￿ The recall time frame of typical health care cost items
should not exceed three to four months, although longer
periods are possible for specific items depending on their
salience (hospital admissions, long-term sick leave)
[9,18,25,26].
￿ Closed questions should be used if possible in order to
support the effects of recognition [27].
Based on this information, the cost items in the question-
naire were divided according to their salience and their
regularity of occurrence. The first part comprises cost com-
ponents and health care utilization items that occur regu-
larly and tend to be relatively unimportant to the patient.
Items with these characteristics include the services of pro-
fessional or informal caregivers, travel expenses, and addi-
tional costs for physical activities related to heart disease
(table 1). The decision which variables would satisfy these
conditions has been based on plausibility and patient
opinion within the asked patient group. The second part
comprised all items that occur regularly but tend to be
more important to patients.
Ingested medications were a mixed case. Recommended
medications for heart disease are similar in the various
guidelines, and their administration is typically regular
and over the long term. Substitutions between various
drugs within the same class may occur periodically [28-
30]. Furthermore medication rates have generally been
observed to remain quite stable after an ACE [31,32].
However, changes in prescribed medications tend to be
Table 1: Cost components measure in cost questionnaire
Cost component Parameter Recall period Valuation*
Utilization of paid and unpaid 
help
Nature of help, duration (hours), outlays 4 weeks Mean gross wage of a housekeeper
Travel expenses Type of transportation, number of rides, cost (if 
public transportation) or kilometers (car)
4 weeks Outlays (public transportation), official 
schedule of travel expenses (car)
Physical activities, gym activities Type of activity, average number per week, 
duration, outlays
4 weeks Average prices per activity
Physician services Specialization of physician, number of 
consultations, services performed
12 weeks Mean reimbursement per consultation
Intake of prescribed medication Name of medication, current daily dosage, 
changes in medication or dosage
12 weeks Official pharmaceutical price list
Intake of unprescribed 
medication
Name of medicine, number and size of packages 
purchased
12 weeks Official pharmaceutical price list
Physical therapeutics/non-
physician services
Type and number of services 12 weeks Pricing schedule of statutory health 
insurance
Alternative care Type and number of services, outlays 12 weeks Outlays or price schedule of alternative 
care
Medical products Type of product, outlays/cost 12 weeks Average market prices
Change in diet Type of dietary changes, estimated additional 
outlays
12 weeks Outlays estimated by patients
Lost productive time Reason for lost productive time, duration 12 weeks Average sex- and age-adjusted labor costs
Inpatient stay Reason for inpatient treatment, duration 12 weeks Average per diem rates**
*Valuation in 2006 prices following suggested unit cost [33].
** Mean department specific hospital cost per day as suggested by Krauth et al. [33].BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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related to an acute event, which might be more important
to the patient. This was resolved by asking the patient for
their current daily intake. A subsequent question asked for
changes in drug prescriptions occurring in the last three
months. Correct recall was supported by "bounded recall"
techniques. Thus, for the 3-month questionnaire, patients
received a list with the discharge medications from cardiac
rehabilitation.
The ordering of the questions was driven by the common
recommendation in questionnaire design to start with
rather easier questions e.g. [11] as well as the aim to avoid
participants' confusion by switching between reference
periods more often than needed. The questionnaire is
available in its original German version as well as in an
English translation which, however, has not been for-
mally assessed [see Additional files 1 and 2].
Costs for medication and medical aids were valued using
standard prices [33]. Reported days off work and hospital
days were multiplied by average labour costs and hospital
costs respectively. All costs are inflation adjusted and pre-
sented in 2006 Euros.
Practicability/acceptability
The feasibility and acceptance of a cost questionnaire are
crucial for its use in health economic studies. This is
assessed by the response rate, which is defined as the pro-
portion of returned questionnaires. As filter questions
were used for each item, missing entries were defined as
either missing information on the filter question itself or
missing further information if the filter question was pos-
itively checked. Acceptance was also assessed by asking
participants to rate the degree of difficulty of filling in the
questionnaire on a four-point Likert scale.
Completeness and face validity
In order to determine the relevant resource categories
related to cardiac problems, eight patients who underwent
rehabilitation care after ACE were interviewed about their
typical medical consumption and other disease-specific
non-medical utilization. They were also asked to rate the
relevance of the different cost items by themselves. This
was used to differentiate between questions in a 4-week
and 3-month recall period. Face validity of the question-
naire was then assessed by medical experts consisting of a
physician at the rehabilitation hospital and two outpa-
tient physicians. They judged the completeness and con-
sistency of the questionnaire draft.
Convergent validity
Convergent validity was tested by comparing the informa-
tion provided by the questionnaire with an alternative
collection method of patient reported data – a prospective
cost diary – which was based on previously tested and
reported instruments [5,13]. Patients completed the cost
diary prospectively over 4 weeks after cardiac rehabilita-
tion. The information from the prospective cost diary was
compared with the information from the retrospective
questionnaire for an overlapping time period of 4 weeks.
As some cost items were retrospectively assessed for the
last 4 weeks (table 1), comparisons were possible for these
cost items. Additional comparisons were possible by
matching data which were asked in date format (hospital
spells, spell off work), by reconstructing the retrospec-
tively given history of medical intake, and by asking the
patients in the tested questionnaire to assign the stated
physician visits within the last 12 weeks to one of three 4
week spells after discharge from rehabilitation hospital.
Criterion validity
For the cost items, days off work and hospital days, a third
"objective" assessment was possible using administrative
data from the statutory sickness funds which constitute
the German public health insurance covering ~90% of the
German general population. However, this analysis was
only performed on a sub-sample, as some patients refused
to allow the sickness fund the release of their data (n =
29), not all sickness funds responded to our request (n =
5), and some patients were privately insured (n = 11).
Overall, the sickness funds provided information for 48
patients.
If patients consented, sickness funds were asked to list all
sick leave and hospitalization days with the respective
diagnoses codes during the 3 months after rehabilitation
treatment (reference period). The validity of the question-
naire was assessed according to these data, which were
considered to be the gold standard because sickness funds
must pay sick benefits and hospital charges based on these
data.
Study design
On admission to the rehabilitation hospital in southern
Germany, 106 consecutive patients requiring rehabilita-
tion (3–4 weeks) after an ACE were recruited. Exclusion
criteria were (as in the subsequent clinical trial) age above
65 years, insufficient command of the German language,
and an ACE occurring more than 3 months before admis-
sion to the rehabilitation hospital.
Patients received the prospective 4-week cost diary upon
discharge from the rehabilitation hospital, while the 3-
month retrospective cost questionnaire was mailed 3
months after discharge. Patients were instructed to com-
plete the questionnaire by themselves.
If necessary, patients were mailed two reminders and, if
they still did not return the questionnaire, they were tele-
phoned. Participants also received a gift coupon of 12   asBMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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an incentive after completing and returning the question-
naire. Monetary incentives have been shown to increase
response rates for health questionnaires [34].
Statistical analysis
Internal consistency was tested using contingent tables
with categorically scaled data. Intraclass correlation coef-
ficients (ICC) between the prospective 4-week cost diary
and the retrospective cost questionnaire were calculated
from metrically scaled data, as this coefficient is a more
suitable measure of agreement than, for example, Pearson
correlation [33]. To test validity, retrospective self-reports
and administrative data were compared by t-test and
intraclass correlation. Self-reported retrospective data and
administrative data were also compared by plotting the
differences between the values against the mean of the val-
ues in order to test for a relationship between the differ-
ence and the magnitude of the two values [35].
Calculations and statistical analysis were performed using
the software package SAS 8.02 (SAS Institute Inc., Cary,
NC, USA).
Ethics
The study was approved by the Ethics Committee of the
State Medical Chamber of Baden-Württemberg
(Landesärztekammer). Informed written consent was
obtained from each individual enrolled into the study.
Results
Patients
The sociodemographic and clinical characteristics of the
106 patients enrolled in the study are shown in table 2.
The sample reflects the typical sex distribution of patients
after an acute cardiac event which is dominated by males.
Feasibility and acceptability
The total response rate of the cost questionnaire was 88%
(93/106). Sixty per cent (57) of the sample returned the
questionnaire without an additional reminder. Roughly
one-fifth (21) of respondents reacted after the first and
another 14% (13) after the second reminder letter. Two
participants only responded after being called. The 13
non-respondents were on average 4.8 years younger than
the respondents (p = 0.04) and were more likely to be
employed full time than respondents (60% vs. 77%).
The 20 filter questions, which had to be checked in each
questionnaire, were used as an indicator of the degree of
completion of the questionnaire. From the total of 1860
(20 × 93) questions to be answered by the 93 responders,
15 (0.8%) questions were not filled in. In addition the
sequence accuracy after the filter question was assessed. In
just two cases a positively checked filter question was not
followed by a meaningful entry, whereas after all nega-
tively checked questions the following detail table
remained (rightly) blank.
Most of the respondents (92%) found the questionnaire
easy or very easy to answer. Information on the average
Table 2: Participant characteristics (n = 106)
Age (years) Insurance status
Mean (SD) 55 (7.6) Statutory health insurance 91 (86%)
Range 30–65 Private health insurance 13 (12%)
Sex n.a. 2 (2%)
Male 90 (85%) Diagnosis
Female 16 (15%) Myocardial infarction 54 (51%)
Vocational education CABG 45 (42%)
No 4 (4%) Angina 7 (7%)
Vocational training 52 (49%) Duration of disease since diagnosis (months)
Technical school 23 (22%)
University/technical college 21 (20%) Mean (SD) 20.6 (47.7)
Other/n.a. 6 (6%) Range 0.5–264
Persons in household NYHA classification
Mean (SD) 2,7 (1,2) class I 88 (83%)
Range 1–6 class II 10 (9%)
Employment status class III 3 (3%)
Full time 66 (62%) class IV 0
Less than full time 4 (9%) n.a. 5(5%)
Unemployed 3 (3%) Self-rated health 3 months after rehabilitation (VAS)
Early retirement 9 (8%)
Regular retirement 16 (15%) Mean (SD) 78.6 (15.8)
Other/n.a. 1 (1%) Range 30–100
NYHA, New York Heart Association range: class I = light limitations, class IV = inability; CABG, coronary artery bypass graft surgery; n.a., not 
available; VAS, visual analogue scale; range: 0 (= worst) to 100 (= best).BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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duration of completion was provided by 88 respondents.
Time for completion was on average 27 minutes (stand-
ard deviation (SD) 25.6, ranging from 4 to 180 minutes,
median 20). For 85% of the sample, completion of the
questionnaire did not take more than 30 minutes.
Convergent validity
Convergent validity of patient information was studied by
comparing the information of the retrospective cost ques-
tionnaire with a prospective diary. The main result of the
comparison is shown in table 3. The ICCs of the com-
pared cost items ranged between 0.57 and 0.90. Except for
medications, the retrospectively measured mean values of
health care utilization tended to be lower than the pro-
spective measurements.
A more detailed analysis of the medications is provided in
table 4. While the names of the products agreed in 61% of
the cases, there was a higher rate of agreement when the
medical agents themselves were analyzed (81%).
Criterion validity
The outcome of the validity analysis comparing the 3-
month patient questionnaire and the sickness fund data is
reported in table 5. The intraclass correlations, used as a
measure of agreement, are generally well above 0.7, which
indicates good agreement. However, the paired t-test
reveals significant differences between the mean values of
sick leave, which leads to an underestimation of the indi-
rect costs. Figure 1 illustrates the differences plotted
against the mean of patient-provided data and adminis-
trative data. The graph shows that underreporting did not
increase with increasing sick leave days.
Based on the full sample (n = 90), patients reported more
sick leave in the questionnaire than in the diary. However,
in the subpopulation for which sickness fund data were
available (n = 48), subjects underreported sick leave days
in the questionnaires over the 3-month period. Compar-
ing the 4-week period covered by the available sickness
fund data and the diary showed that the mean sick leave
days agreed well between the diaries and the sickness fund
data (17.1 vs. 17.6 days, p = 0.60), whereas there was
slight underreporting of sick leave in the questionnaire
(16.3 days, p = 0.24).
Health care and disease-related costs
The results of the cost measurement analysis are shown in
table 6. As expected, the indirect costs accounted for the
major part of the disease-related costs. Among the direct
medical costs, hospitalization accounted for most of the
costs followed by the prescribed drugs, reflecting the great
relevance of pharmaceutical treatment in patients after
ACE. Most of the direct cost items are skewed to the right,
typical of health care costs. Indirect and, therefore, total
costs are minimally skewed, but instead have a u-shaped
distribution because of a significant proportion of
patients with minimum or maximum indirect costs.
Discussion
Health economic studies incorporating a societal perspec-
tive and performed alongside clinical trials must rely at
least partially on patient-based information on resource
consumption. This study's aim was to describe the devel-
opment of a questionnaire measuring direct and indirect
costs in patients after an acute cardiac event and to test its
properties in terms of feasibility and aspects of validity.
Study design
The questionnaire was developed based on the results of
survey research and cognitive psychology regarding the
appropriate time frame of the cost items required to com-
pletely assess costs in an economic evaluation. In the
development of this retrospective questionnaire, the
major issues concerning the accuracy of utilization meas-
urement, which were summarized recently by Bhandari
and Wagner, were considered: the questionnaire was
developed specifically for the sample population and
their utilization patterns, recall aspects were taken into
account, different forms of data collection were com-
pared, and the instrument was finally revised with
improved instructions [15]. By explicitly describing the
Table 3: Comparison of prospective cost diary and retrospective questionnaire for overlapping time (n = 90)*
Retrospective cost questionnaire Cost diary ICC p**
Mean (SD) Mean (SD)
Number of physician visits 1.9 (1.9) 2.2 (2.2) 0.64 0.13
Inpatient days 0.54 (2.1) 0.54 (2.0) 0.90 0.99
Days off work 13.8 (14.9) 15.7 (14.0) 0.77 0.06
Number of drugs 4.1 (1.5) 3.9 (1.4) 0.72 0.09
Cost of medical intake (€) 2.9 (1.5) 2.6 (1.3) 0.57 0.04
Cost of medical aids (€) 162.3 (258.6) 175.5 (264.6) 0.72 0.52
*For three participants, comparison was not feasible as they did not return their cost diaries.
**Wilcoxon sign rank test.BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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development process and the validation, we seek to con-
tribute to the standardization of cost instruments and
their standardized validation.
Acceptability and feasibility
The questionnaire was easy to use and showed a high
response rate of 88%. The average completion time of 27
minutes is at the upper time limit acceptable to patients
[36]. As the median is considerably lower (20 minutes)
and only 15% of subjects required more than 30 minutes
for completion, the time burden was probably acceptable
for most subjects. However, this could be a practical
research problem if other patient-oriented outcomes are
measured in addition to costs. As cost measurement
showed that a substantial percentage of costs are due to
just a few main cost drivers such as days off work, hospital
admissions, and medications, it would be possible to
reduce the number of cost items and related utilization
questions without losing too much relevant information.
However, this must be decided specifically for each study
as there is a trade off between level of detail, accuracy and
completeness versus acceptability.
The response pattern indicates the usefulness of remind-
ers. Even the second reminder letter substantially raised
the response rate whereas a third contact by telephone did
not show a further significant improvement in participa-
tion. A third reminder letter is also probably useless
because, by the time a third letter is sent, the likelihood of
recall error and telescoping effects increases.
A problem in the study was the selection bias of respond-
ers. The age difference between responders and non-
responders was 5 years, and the percentage of non-
responders in full-time employment was substantially
higher. Comparable studies on patient-reported utiliza-
tion did not find differences in compliance with respect to
age but with respect to marital status [5]. The lower
response rate of patients in full-time employment may be
due to their tighter time schedule. Thus, the length of the
questionnaire should be as short as possible, and the
importance of continued response should be thoroughly
explained to patients when motivating them to participate
in the study. In clinical trials, results should be checked for
an influence of full-time employment status.
Assessment of validity
Our comparison of the questionnaire with a patient diary
and with data from sickness funds regarding some key var-
iables supports its validity for cost measurement. The
questionnaire agreed reasonably with the patient diary for
variables that could be compared over the time period of
4 weeks. Comparison of medications showed that 61%
agreed in terms of names and 81% agreed with respect to
the active agent. Comparison of hospitalization, sick
leave, and physician visits showed moderate to good cor-
relation, although a significant difference in the level was
observed. There was a tendency to underreporting com-
pared with the prospective data and the administrative
data, which has often been reported in studies analyzing
retrospective patient-reported data compared with admin-
istrative or provider data [4,5,12,37,38].
In particular, the underreporting of sick leave and, there-
fore, indirect costs must be noted as this cost component
is the dominant cost driver. This corresponds with other
Table 4: Comparison of medications measured by cost diary and retrospective questionnaire (n = 90)*
Reliability analysis Medication (sales name) Medication (generic name/agent)
Questionnaire Diary
Yes Yes 274 (61.3%) 325 (80.8%)
Yes No 77 (17.2%) 28 (7.0%)
No Yes 95 (21.3%) 48 (11.9%)
No No 1** (0.2%) 1** (0.2%)
* For three participants, comparison was not feasible as they did not return their cost diaries.
**Patients who did not report any medical intake.
Table 5: Comparison of questionnaire and sickness fund data (n = 48)
Retrospective 
cost questionnaire
Sickness fund
 data
Zero difference 
(+/- 1)
ICC p*
Mean (SD) Mean (SD) n (%)
Days off work hospitalized 1.8 (7.45) 1.8 (7.5) 42 (87.5) 0.92 0.92
Days off work not hospitalized 25.3 (33.4) 29.1 (33.5) 25 (52.1) 0.94 0.03
Total days of sick leave 27.2 (35.2) 30.9 (34.9) 29 (60.4) 0.94 0.03
*Wilcoxon sign rank test.BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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recent studies that have also found underreporting of lost
productive time [9,38]. One reason for this underreport-
ing seems to be partly a lower response rate in patients
who are active in the labor force. Therefore, measures
aimed at increasing the response rate of working patients
might lower the extent of underreporting in this impor-
tant cost component.
A detailed analysis showed that the major difference in the
mean value was effectively caused by single cases for
which there was a great discrepancy between self-reported
and administration data. It seemed that patients who were
jobless at the time of the cost survey did not record sick
leave although they were (correctly) listed in the sick leave
data. Thus, describing this case in the instructions accom-
panying the questionnaire may increase agreement
between the two sources.
Despite the good concordance indicated by measures of
(linear) agreement, absolute utilization was mostly
underreported when the results of the questionnaire were
compared with administrative data and the diary. As this
tendency does not appear to depend on baseline charac-
teristics or health status, it seems unlikely that such devia-
tions could bias the cost measurement of disease-related
costs when differences between treatment groups are ana-
lyzed, as is usually the case in health economic evaluation
studies.
As expected, the disease-related costs measured by this
questionnaire are dominated by high indirect costs, which
are known to be an important consequence of heart dis-
ease [39]. The information on the distribution and vari-
ance in the data provides valuable information for
statistical planning of health economic studies. Although
the questionnaire has been developed to cover the typical
utilization patterns of patients after an ACE, it could be
adapted to other diseases, including layout and instruc-
tions, with minimal effort.
Limitations
There were limitations of this study which need to be
mentioned. As ACE has a high incidence in age groups
over 65 years, the findings are not totally representative
for the unrestricted population. No significant age-related
differences were found in the quality of reporting in our
study. This corresponds with the findings of Ritter et al.,
who did not detect any reporting differences according to
demographic characteristics [4]. Additional validation
research focusing also on higher age classes would be of
high interest.
The size of the study was planned to indicate whether the
measurement approach was feasible and reasonably valid.
For more detailed analysis, a larger study including a com-
parison with administrative data regarding medication
and physician visits would be desirable. Due to various
reasons, the comparison of the questionnaire with admin-
istrative data was just possible for n = 48 representing 45%
of the starting sample of 106, which is a significant loss in
power and might induce bias. The described selection
process implies that for the n = 29 patients who did not
sign the related patient agreement a systemic bias cannot
be fully excluded, although there is no intuitive assump-
tion as to how and for what reason the response pattern
and agreement would systematically vary with the fact
that the participants disagreed to contact. The information
for the other cases n = 16 is in technical terms missing at
random and therefore unlikely to introduce any bias for
the results of the remaining sample.
As health care utilization is potentially subject to treat-
ment variability, generalizability across countries cannot
be taken for granted. In the case of secondary prevention
after ACE, comparable treatment patterns are suggested
across countries [28,30], and thus the basic structure of
potential utilization should be comparable between
countries. Differences in resource availability and accessi-
bility to health care systems will mainly impact the fre-
quency of utilization (e.g. number of physician visits or
special procedures in hospital), which can then be cap-
tured by the questionnaire.
Bubble plot of difference (self-report–administrative data) by  mean days off work (n = 48) Figure 1
Bubble plot of difference (self-report–administrative 
data) by mean days off work (n = 48). The bold solid line 
represents the regression line; the thin line is drawn at zero 
representing exact agreement. The bubble size is proportion-
ate to the number of patients with corresponding values.BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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The severity of the disease state may potentially have an
impact on questionnaire acceptance. Considering the dis-
ease classification according to the New York Heart Asso-
ciation (NYHA) and self-rated health, the sample in this
study was moderately affected by the consequences of
their ACE. As there was only a weak correlation between
measures of disease severity and questionnaire accept-
ance, this provides some evidence that the questionnaire
can also be used in more severely affected populations as
long as patients are cognitively and physically capable of
completing the forms.
Also asking for information in overlapping periods might
have had a positive impact on patients' commitment and
their thoroughness in completing the questionnaire,
resulting in higher acceptance and questionnaire agree-
ment than in a non-clinical trial setting. This effect cannot
be excluded for every research dealing with repeated
measurements and might be dampened in this case by the
fact that in most cases a time span of 8 weeks was in
between the administration of the two instruments.
A final limitation of this questionnaire is that it is targeted
on cardiac patients. It should be noted that before apply-
ing instruments to other areas of diseases a similar process
of adaptation is recommended in order to capture the dis-
ease specific health care utilization. This process could
include a literature review of main treatment patterns and
examination and assessment of the draft instrument by
medical experts as well as patients.
Conclusion
With the population under study the questionnaire was
well accepted and showed good correlation with alterna-
tive measurement approaches. This preliminary assess-
ment showed some promising characteristics of this
questionnaire in different aspects of validity for patients
with ACE and might present a possible alternative for the
measurement of study costs in settings where the collec-
tion of administrative data is not feasible. However, addi-
tional research and more extensive tests would be
worthwhile.
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Table 6: Cost of care (for 3 months) based on retrospective data (n = 93)
Percent Mean SD Range Skewness
Direct medical cost* 13.1% 1,050.5 1,767.5 83.9–14070.8 5.24
Hospitalization 43.5% 457.0 1714.7 0.0–13,865.6 6.07
Prescription drugs 23.8% 250.3 119.6 26.9–778.6 1.27
Medical aids 18.9% 198.5 408.0 0.0–3,236.4 5.02
Physician 12.7% 133.0 232.4 0.0–1726.0 5.12
Non-prescription drug 0.8% 8.1 51.1 0.0–470.7 8.45
Courses 0.2% 2.0 11.2 0.0–77.2 5.74
Alternative care 0.1% 1.5 9.2 0.0–76.7 7.08
Non-medical cost* 2.6% 212.2 357.7 0.0–2,112.4 3.52
Services (paid/unpaid) 52.4% 111.2 341.1 0.0–2,036.9 4.08
Activities 20.3% 43.2 41.8 0.0–196.2 0.56
Additional cost for diet 18.7% 39.6 87.9 0.0–385.8 2.40
Travel expenses 8.6% 18.2 40.9 0.0–277.8 3.76
Indirect cost* 84.2% 6,754.0 8,433.5 0.0–2,1673.7 0.77
Time off work for physician visits 0.3% 18.6 53.8 0.0–273.4 3.10
Time off work 99.7% 6,735.5 8,434.9 0.0–21,804.5 0.77
Total cost 100.0% 8,016.8 9,122.5 83.9–34,522.0 0.85
*Percentage of total cost.BMC Health Services Research 2008, 8:187 http://www.biomedcentral.com/1472-6963/8/187
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